



September 8, 2016

## **Catalyst Pharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference**

CORAL GABLES, Fla., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw's 18<sup>th</sup> Annual Global Investment Conference, which is being held on September 12-13, 2016 at the New York Palace Hotel in New York.

The presentation will occur on Monday, September 12<sup>th</sup> at 10:25 AM ET. The presentation materials will be posted at [www.catalystpharma.com](http://www.catalystpharma.com) in the Investor section under Events and Presentations.

### **About Catalyst Pharmaceuticals**

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette's Disorder. Firdapse® for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and orphan drug designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.

Catalyst is also developing CPP-115 to treat infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette's Disorder. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).

### **Forward-Looking Statements**

*This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2015 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.*

Investor Contact

Brian Korb

The Trout Group LLC

(646) 378-2923

[bkorb@troutgroup.com](mailto:bkorb@troutgroup.com)

Company Contact

Patrick J. McEnany

Catalyst Pharmaceuticals

Chief Executive Officer

(305) 420-3200

[pmcenany@catalystpharma.com](mailto:pmcenany@catalystpharma.com)

Media Contacts

David Schull

Matt Middleman, M.D.

Russo Partners

(212) 845-4271

(212) 845-4272

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

[matt.middleman@russopartnersllc.com](mailto:matt.middleman@russopartnersllc.com)

 Primary Logo

Source: Catalyst Pharmaceuticals, Inc.

News Provided by Acquire Media